However, these results are similar to the negative results of Phase II trial in melanoma with ISIS3521 (an antisense oligonucleotide against PKCα) in which no responses were seen in 23 chemo-naïve patients (Fumoleau et al, 2000). This evidence concerns the gene PRKCA and melanoma.